ERBB2 and breast carcinoma: Approximately 15–20% of breast cancers are classified as HER2-positive (HER2+), a subgroup of tumors with a more aggressive clinical phenotype and worse prognosis due to unregulated cell growth and abnormal survival mediated by overexpression of the HER2 protein (2–8).